Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2014 / Cilt: 24 - Sayı: 1

Kanser Hastalarında Tamamlayıcı/Alternatif Tedavi: Bir Anket Çalışması

Complementary/Alternative Medicine Experience in Cancer Patients: A Questionnaire-Based Survey

Pages
45–53
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Randomized clinical trials are needed to determine possible risks and benefits associated with CAM use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A study was designed to evaluate the frequency of complementary/alternative therapy (CAM) knowledge and usage in cancer patients.
📊
Key Findings & Data:A 23-item survey questionnaire was administered to 494 patients who received chemotherapy in the medical oncology department of three hospitals between June 2011 and December 2011.
💡
Conclusion & Impact:Randomized clinical trials are needed to determine possible risks and benefits associated with CAM use.
🔬Design:Survey & Empirical Study
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

A study was designed to evaluate the frequency of complementary/alternative therapy (CAM) knowledge and usage in cancer patients. A 23-item survey questionnaire was administered to 494 patients who received chemotherapy in the medical oncology department of three hospitals between June 2011 and December 2011. After giving written informed consent, patients completed a selfadministered questionnaire. Differences among participants were assessed by using the SPSS 17.0 software. Of the 494 patients, 48% had heard of CAM, and 23.5% had used at least one CAM model. Herbs and vitamins were the most frequently used approach (82.2%). The most commonly used herb was the stinging nettle (55.5%). Marital status (p= 0.003), educational status (p< 0.001), monthly income (p< 0.001), knowledge about disease (p< 0.001), family history of comorbidity (p<0.012), and place of residence (0.004) were statistically significant for knowledge about CAM. However, marital status (p< 0.001), comorbidity (p= 0.004), educational status (p=0.006), family history of comorbidity (p= 0.008), and family history of cancer (p= 0.03) were statistically significant for CAM use. Logistic regression analysis showed that educational status (p=0.015), high monthly income (p=0.03), knowledge about disease (p= 0.005), and a family history of comorbidity (p= 0.005) were statistically significant for knowledge about CAM. Otherwise, only marital status (p< 0.001) and comorbidity (p= 0.04) were determined as independent factors for CAM use. Health professionals should routinely ask their patients about CAM use and discuss the reasons and outcomes of use. Randomized clinical trials are needed to determine possible risks and benefits associated with CAM use.

Özet

Kanser hastalarında tamamlayıcı/alternatif tedaviyi (TAT) bilme ve kullanma sıklığını değerlendirmek için bu çalışma dizayn edildi. Haziran 2011 ile aralık 2011 tarihleri arasında, 3 hastanenin medikal onkoloji departmanında tedavi gören toplam 494 hastaya 23 soruluk bir anket uygulandı. Hastalara yazılı bilgilendirilmiş onam formu imzalatıldıktan sonra, kendilerinin doldurması için anket formları verildi. Katılımcılar arasındaki farklar SPSS.17 paket programıyla değerlendirildi. Toplam 494 hastanın %48’i TAT terimini duymuş, %23.5’I de en az bir TAT modelini kullanmıştı. Bitkiler ve vitaminler en sık kullanılan yaklaşımdı (%82.2). En sık kullanılan bitki ise ısırgan otuydu (%55.5). Medeni durum (p= 0.003), eğitim durumu (p< 0.001), aylık gelir düzeyi (p< 0.001), hastalığı bilme durumu (p< 0.001), ailede komorbidite varlığı (p< 0.012) ve yaşadığı yer (p= 0.004), TAT hakkında bilgi sahibi olma durumuyla istatistiksel olarak anlamlı bulundu. Bununla beraber, TAT kullanımıyla medeni durum (p< 0.001), ek hastalık varlığı (p=0.004), eğitim durumu (p= 0.006), ailede komorbidite varlığı (p= 0.008) ve ailede kanser varlığı (p= 0.03) istatistiksel olarak anlamlı bulundu. Lojistik regresyon analizi yapıldığında ise, eğitim durumu (p=0.015), yüksek aylık gelir düzeyi (p= 0.03), hastalık hakkında bilgi sahibi olma durumu (p= 0.005), ailede komorbidite varlığı (p= 0.005) TAT hakkında bilgi sahibi olma durumuyla ilişkili idi. Sadece, medeni durum (p< 0.001) ve komorbidite varlığı (p= 0.04) TAT kullanımıyla ilişkili olan bağımsız faktörler olarak saptandı. Sağlık çalışanları, rutin olarak hastalarına TAT kullanımını sormalı ve sebepleriyle kullanımdan kaynaklanabilecek sonuçları tartışmalıdır. TAT kullanımının olası risk ve faydalarını saptamaya yönelik randomize çalışmalara ihtiyaç vardır.

🔖

Cite This Article

DOĞU, G. G., KARGI, A., TANRIVERDİ, Ö., YAREN, A., DEMIRAY, G., TASKOYLU, B. Y., ERGİN, A. (2014). Kanser Hastalarında Tamamlayıcı/Alternatif Tedavi: Bir Anket Çalışması. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 24 - Sayı: 1, 45–53. https://ajindex.com/articles/323163

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. NCCAM. What is complementary and alternative medicine (CAM)? National Center for Complementary and Alternative Medicine website. Available at: http://nccam.nih.gov/health/ whatiscam/#6. Accessed May 1, 2007.
  2. Ucan O, Pehlivan S, Ovayolu N, etal. The use of complementary therapies in cancer patients: a questionnairebased descriptive survey from southeastern Turkey. Am J Clin Oncol 31: 589-94, 2008.
  3. Tas F, Ustuner Z, Can G, et al. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol 44: 161-167, 2005. Acıpayamlı O. Folk medicine in Turkish folklore (Article in Turkish). Dtcfder 26: 1-2, 1969.
  4. Ceylan S, Hamzaoglu O, Komurcu S, et al. Survey of the use of complementary and alternative medicine among Turkish cancer patients. Complement Ther Med 10: 94-99, 2002.
  5. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18: 2505-2514, 2000;
  6. Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22: 671-677, 2004.
  7. Milazzo S, Ernst E. Newspaper coverage of complementary and alternativ therapies for cancer-UK 2002–2004. Support Care Cancer 14: 885-889, 2006. Turkdogan O. Culture and Health Disease System (article in Turkish). MEB Publications 1991: 145-147.
  8. Lee MM, Lin SS, Wrensch MR, et al. Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92: 42-47, 2000.
  9. Richardson MA, Sanders T, Palmer JL, et al. Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18: 2505-2514, 2000.
  10. Crocetti E, Crotti N, Feltrin A, et al. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 34: 324-328, 1998.
  11. Samur M, Bozcuk HS, Kara A, et al. Factors associated with utilization of nonproven cancer therapies in Turkey. Support Care Cancer 5: 452-458, 2001.
  12. Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16: 655-663, 2005.
  13. Zollman C, Vickers A. ABC of complementary medicine. Users and practitioners of complementary medicine. Br Med J 319: 836-838, 1999.
  14. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in altern